Disease Markers

Research Article

Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Table 1

Clinical and virological details of the treatment-naïve HBV-infected patients.


Characteristic	HBeAg-positive patients ( =70)			HBeAg-negative patients ( =41)
Characteristic	Immune-tolerant phase ( =21)	Immune-clearance phase (=49)	-value	Low replicative phase ( =29)	Reactivation phase ( =12)	-value

Gender, male, (%)	7 (33.33)	32 (65.31)	0.027	18 (62.07)	11 (91.67)	0.073
Age, years	38 (33, 45)	32 (27, 38)	0.007	38 (31, 42)	38 (30, 44)	0.682
HBV DNA, log₁₀ IU/mL	8.57 (8.12, 9.00)	8.52 (7.59, 9.00)	0.636	2.37 (1.94, 3.04)	4.27 (3.44, 5.08)	< 0.001
HBsAg, IU/mL	52010 (36221, 77630)	27173 (5731, 49565)	0.009	1516 (231, 4814)	1176 (608, 7741)	0.921
HBeAg, COI	1710 (1447, 1964)	1674 (853, 1842)	0.231	/	/	/
ALT, U/L	25 (19, 33)	76 (49, 243)	< 0.001	19 (17, 28)	54 (39, 79)	< 0.001
AST, U/L	25 (19, 30)	42 (31, 100)	< 0.001	21 (18, 25)	33 (25, 51)	< 0.001
ALB, g/L	39 (38, 43)	41 (37, 44)	0.714	43 (40, 45)	44 (40, 45)	0.854
TBIL, μmol/L	12.60 (9.50, 14.90)	14.70 (11.50, 19.20)	0.040	11.20 (8.70, 16.70)	16.60 (10.50, 25.00)	0.088
γ-GT	19.50 (13.50, 23.00)	30.00 (18.00, 55.50)	0.010	20.00 (16.00, 29.00)	25.50 (21.50, 47.30)	0.015

Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALB: albumin; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; n: number of cases; TBIL: total bilirubin; γ-GT: γ-glutamyltransferase. All the results of continuous variable are described as median (interquartile range).